AGM
INMB icon

Alpine Global Management’s INmune Bio INMB Stock Holding History

Alpine Global Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,559
Closed -$102K – 295
2024
Q2 		$102K Buy
+11,559
New +$114K 0.02% 408

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Alpine Global Management's INMB Position: Q3 2024 in Review

Alpine Global Management sold out of INmune Bio (INMB) in Q3 2024, closing a stake of 11,559 shares — an estimated $102K sold.

Alpine Global Management first reported a position in INMB in Q2 2024 and held it in 1 quarter. The position peaked at $102K in Q2 2024. 67 funds tracked by Wall St. Rank hold INMB as of Q3 2024.

  • Alpine Global Management reported no remaining INmune Bio position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 11,559 INmune Bio shares in Q3 2024, an estimated $102K.
  • Alpine Global Management first reported a position in INmune Bio in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's INmune Bio position peaked at $102K in Q2 2024.
  • 67 funds tracked by Wall St. Rank held INmune Bio as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.